CervoMed Inc. (CRVO) - Total Liabilities
Based on the latest financial reports, CervoMed Inc. (CRVO) has total liabilities worth $4.60 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CervoMed Inc. cash conversion from operations to assess how effectively this company generates cash.
CervoMed Inc. - Total Liabilities Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are CervoMed Inc.'s assets to evaluate the company's liquid asset resilience ratio.
CervoMed Inc. Competitors by Total Liabilities
The table below lists competitors of CervoMed Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eagle Veterinary Technology Co.Ltd
KQ:044960
|
Korea | ₩10.35 Billion |
|
Level Biotechnology
TWO:3118
|
Taiwan | NT$237.03 Million |
|
Galaxia SM Inc
KO:011420
|
Korea | ₩11.74 Billion |
|
FACB Industries Incorporated
KLSE:2984
|
Malaysia | RM22.11 Million |
|
DJ Mediaprint & Logistics Limited
NSE:DJML
|
India | Rs365.72 Million |
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
USA | $42.71 Million |
|
Podium Minerals Ltd
AU:POD
|
Australia | AU$1.42 Million |
|
Bafna Pharmaceuticals Limited
NSE:BAFNAPH
|
India | Rs694.55 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down CervoMed Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CRVO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CervoMed Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CervoMed Inc. (1998–2024)
The table below shows the annual total liabilities of CervoMed Inc. from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.88 Million | +49.45% |
| 2023-12-31 | $2.60 Million | -80.27% |
| 2022-12-31 | $13.16 Million | +349.35% |
| 2021-12-31 | $2.93 Million | +0.42% |
| 2020-12-31 | $2.92 Million | -29.65% |
| 2019-12-31 | $4.14 Million | +59.98% |
| 2018-12-31 | $2.59 Million | -47.30% |
| 2017-12-31 | $4.92 Million | -40.77% |
| 2016-12-31 | $8.30 Million | +258.02% |
| 2015-12-31 | $2.32 Million | -49.75% |
| 2014-12-31 | $4.61 Million | -61.17% |
| 2013-12-31 | $11.88 Million | -43.03% |
| 2012-12-31 | $20.85 Million | +5.99% |
| 2011-12-31 | $19.68 Million | +254.17% |
| 2010-12-31 | $5.56 Million | +46.60% |
| 2009-12-31 | $3.79 Million | -23.03% |
| 2008-12-31 | $4.92 Million | -35.30% |
| 2007-12-31 | $7.61 Million | +5222.53% |
| 2006-12-31 | $142.96K | +50.70% |
| 2005-12-31 | $94.86K | -99.51% |
| 1999-12-31 | $19.41 Million | +49.31% |
| 1998-12-31 | $13.00 Million | -- |
About CervoMed Inc.
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more